Topics

Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

02:17 EST 29 Nov 2018 | GlobalNewsWire (2014)
This article has expired, however you can still download the PDF.
Preview:
This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn's, Bronchopulmonary dysplasia, Epilepsy and Stroke Amsterdam, The Netherlands - 29 November 2018 ...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates."

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system.  Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...